PTC Therapeutics Aktie

PTC Therapeutics für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1W0MW / ISIN: US69366J2006

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
25.04.2025 15:14:48

PTC Therapeutics Get Positive CHMP Opinion For Sephience For The Treatment Of Phenylketonuria

(RTTNews) - PTC Therapeutics, Inc. (PTCT) Friday said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Sephience for the treatment of phenylketonuria, an inherited genetic disorder.

The New Drug Application (NDA) for sepiapterin is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2025. The drug is also under review in several other countries including Japan and Brazil.

"We look forward to initiating the European launch immediately following the adoption of this positive opinion by the European Commission," said Matthew B. Klein, Chief Executive Officer of PTC Therapeutics.

Analysen zu PTC Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

PTC Therapeutics Inc 52,50 -0,94% PTC Therapeutics Inc